Monitoring Agency Report for the quarter ended 31-03-2026
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fischer Medical Ventures Ltd submitted its quarterly monitoring report for Q4FY26 regarding utilization of Rs. 358.46 crore raised through a preferential issue of equity shares and convertible warrants. The Monitoring Agency, Infomerics Valuation and Rating Limited, confirmed that Rs. 280.93 crore has been utilized as of March 31, 2026, with no deviations from the stated objects. The company utilized Rs. 10.53 crore received during Q4FY26 from warrant conversion towards repayment of an unsecured loan to its wholly-owned subsidiary TMVIPL. The issue consists of 1,03,01,547 equity shares (Rs. 241.05 crore) and 44,17,000 outstanding warrants (exercisable by August 2026). The funds are deployed for growth objectives in imaging technologies and general corporate purposes. The company also completed a 10:1 stock split in Q2FY26.
Positive signal for investors as the monitoring agency confirms full compliance with fund utilization norms and no material deviations. The outstanding warrants represent potential future dilution of approximately 44.17 lakh shares. The loan repayment to the promoter group subsidiary (TMVIPL) is being made as disclosed.